GDNF delivery for Parkinson's disease.
暂无分享,去创建一个
S. Gill | N. Patel | S S Gill | N K Patel | Nikunj K. Patel
[1] Wiklund Ra,et al. First of two parts , 1997 .
[2] S. Leurgans,et al. Objective changes in motor function during placebo treatment in PD , 2000, Neurology.
[3] B. Winblad,et al. Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.
[4] D. Casper,et al. EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture , 1991, Journal of neuroscience research.
[5] P. Gluckman,et al. Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system , 1999, Progress in Neurobiology.
[6] E D Louis,et al. Mortality from Parkinson disease. , 1997, Archives of neurology.
[7] J. Benoit,et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. , 2004, Biomaterials.
[8] M. Dragunow,et al. The role of neuronal growth factors in neurodegenerative disorders of the human brain , 1998, Brain Research Reviews.
[9] A. Björklund,et al. Localized striatal delivery of GDNF as a treatment for Parkinson disease , 2004, Nature Neuroscience.
[10] W. Frey,et al. Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.
[11] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[12] P. Distefano,et al. Differential distribution of exogenous BDNF, NGF, and NT‐3 in the brain corresponds to the relative abundance and distribution of high‐affinity and low‐affinity neurotrophin receptors , 1995, The Journal of comparative neurology.
[13] Zhiming Zhang,et al. Neuroprotective and neurorestorative properties of GDNF , 1998, Annals of neurology.
[14] E. Arenas,et al. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo , 1995, Neuron.
[15] S. Apfel,et al. Neurotrophic Factor Therapy – Prospects and Problems , 2001, Clinical chemistry and laboratory medicine.
[16] I. Date,et al. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice , 1998, Neuroreport.
[17] E. Pothos,et al. Presynaptic Recording of Quanta from Midbrain Dopamine Neurons and Modulation of the Quantal Size , 1998, The Journal of Neuroscience.
[18] G. Gerhardt,et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.
[19] E. Arenas,et al. Stem cells in the treatment of Parkinson’s disease , 2002, Brain Research Bulletin.
[20] J. Engele,et al. Effects of glial cell line-derived neurotrophic factor (GDNF) on dopaminergic neurons require concurrent activation of cAMP-dependent signaling pathways , 1996, Cell and Tissue Research.
[21] F. Hefti,et al. Trophic actions of IGF-I, IGF-II and insulin on cholinergic and dopaminergic brain neurons. , 1991, Advances in experimental medicine and biology.
[22] P F Morrison,et al. Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[23] P F Morrison,et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. , 1999, Journal of neurosurgery.
[24] Timothy Sendera,et al. Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.
[25] F. Gage,et al. Lentiviral vectors: regulated gene expression. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] J. Louis,et al. GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF , 1996, Cell.
[27] H. Thoenen,et al. Neurotrophic factors and neuronal death. , 2007, Ciba Foundation symposium.
[28] D. Choi-Lundberg,et al. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. , 1995, Brain research. Developmental brain research.
[29] Q. Yan,et al. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons , 1995, Nature.
[30] Y Agid,et al. Dopaminergic cell group A8 in the monkey: Anatomical organization and projections to the striatum , 1999, The Journal of comparative neurology.
[31] Chien-ping Wu,et al. GDNF Acutely Potentiates Ca2+ Channels and Excitatory Synaptic Transmission in Midbrain Dopaminergic Neurons , 2003, Neurosignals.
[32] Mark Stacy,et al. Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.
[33] J. Treanor,et al. Characterization of Two Distinct Monoclonal Antibodies Specific for Glial Cell Line‐Derived Neurotrophic Factor , 1998, Journal of neurochemistry.
[34] L. Belluscio,et al. NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of expression , 1990, Neuron.
[35] M. Tuszynski,et al. Neurotrophin gene therapy in CNS models of trauma and degeneration. , 1998, Progress in brain research.
[36] R. Lindsay,et al. The Neurotrophins NT-4/5 and BDNF Augment Serotonin, Dopamine, and GABAergic Systems during Behaviorally Effective Infusions to the Substantia Nigra , 1994, Experimental Neurology.
[37] K. Unsicker,et al. Transforming growth factor-beta promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity. , 1994, Neuroscience.
[38] D J Brooks,et al. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.
[39] W. Mark Saltzman,et al. Localized Delivery of Proteins in the Brain: Can Transport Be Customized? , 1998, Pharmaceutical Research.
[40] I. Date,et al. MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF) , 1990, Brain Research.
[41] A. Davies,et al. GDNF is an age-specific survival factor for sensory and autonomic neurons , 1995, Neuron.
[42] P. Ernfors,et al. Positive and negative interactions of GDNF, NTN and ART in developing sensory neuron subpopulations, and their collaboration with neurotrophins. , 2000, Development.
[43] O. Lindvall,et al. Coexpression of neurotrophins and their receptors in neurons of the central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Sofroniew,et al. Nerve growth factor signaling, neuroprotection, and neural repair. , 2001, Annual review of neuroscience.
[45] R. Jain,et al. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. , 1990, Cancer research.
[46] O. Lindvall,et al. Clinical observations after neural transplantation in Parkinson's disease. , 2000, Progress in brain research.
[47] P. Aebischer,et al. Glial cell line‐derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones , 1994, Neuroreport.
[48] S. Whittemore,et al. Ret-dependent and -independent Mechanisms of Glial Cell Line-derived Neurotrophic Factor Signaling in Neuronal Cells* , 1999, The Journal of Biological Chemistry.
[49] O. Hassani,et al. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat , 1997, Brain Research.
[50] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[51] M. Mattson. Neuroprotective Signal Transduction , 1997, Nature Medicine.
[52] E. Arenas,et al. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons , 1995, The Journal of cell biology.
[53] Frank Costantini,et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret , 1994, Nature.
[54] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[55] M. Bothwell,et al. Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons , 1992, Neuron.
[56] R. Levi‐montalcini. The nerve growth factor: thirty‐five years later. , 1987, The EMBO journal.
[57] Richard Grondin,et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.
[58] B. Winblad,et al. Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report) , 1992 .
[59] L. Olson. Toward trophic treatment in parkinsonism: A primate step , 1996, Nature Medicine.
[60] P. Aebischer,et al. Neuronal GDNF Expression in the Adult Rat Nervous System Identified By In Situ Hybridization , 1997, The European journal of neuroscience.
[61] Rhonda,et al. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[62] S H Appel,et al. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer disease , 1981, Annals of neurology.
[63] A. Björklund,et al. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease , 1997, Neuroscience.
[64] L A Beckett,et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. , 1996, The New England journal of medicine.
[65] J. Dartigues,et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[66] Mart Saarma,et al. The GDNF family: Signalling, biological functions and therapeutic value , 2002, Nature Reviews Neuroscience.
[67] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[68] Weng Tao,et al. Differential in Vivo Effects of Neurturin and Glial Cell-Line-Derived Neurotrophic Factor , 1999, Experimental Neurology.
[69] G. Gerhardt,et al. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. , 1997, The Journal of pharmacology and experimental therapeutics.
[70] S. McMahon,et al. Potent analgesic effects of GDNF in neuropathic pain states. , 2000, Science.
[71] T. Hagg,et al. Glial cell line‐derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats , 1997, The Journal of comparative neurology.
[72] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.
[73] S. Gill,et al. Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.
[74] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[75] R. Lewis,et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. , 2002, Human gene therapy.
[76] G. Gerhardt,et al. In VivoMicrodialysis Studies of Somatodendritic Dopamine Release in the Rat Substantia Nigra: Effects of Unilateral 6-OHDA Lesions and GDNF , 1997, Experimental Neurology.
[77] P F Morrison,et al. High-flow microinfusion: tissue penetration and pharmacodynamics. , 1994, The American journal of physiology.
[78] P. Follesa,et al. Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem: an immunohistochemical study of prenatal, neonatal and adult brains , 2002, Journal of Chemical Neuroanatomy.
[79] J. Ridet,et al. Recombinant proteins for neurodegenerative diseases: the delivery issue , 2001, Trends in Neurosciences.
[80] K. Jellinger,et al. Progressive supranuclear palsy: clinico-pathological and biochemical studies. , 1980, Journal of neural transmission. Supplementum.
[81] J. Mitrofanis,et al. Distribution of various neurochemicals within the zona incerta: an immunocytochemical and histochemical study , 1999, Anatomy and Embryology.
[82] F. Sohrabji,et al. Neuronal colocalization of mRNAs for neurotrophins and their receptors in the developing central nervous system suggests a potential for autocrine interactions. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[83] F. Collins,et al. Purification and Initial Characterization of Rat B49 Glial Cell Line‐Derived Neurotrophic Factor , 1994, Journal of neurochemistry.
[84] M. Beck,et al. Motoneuron cell death and neurotrophic factors: Basic models for development of new therapeutic strategies in ALS , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[85] V. Hamburger,et al. A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180. , 1954, Proceedings of the National Academy of Sciences of the United States of America.
[86] P. Gluckman,et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases , 2000, Progress in Neurobiology.
[87] B J Hoffer,et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. , 1989, Archives of neurology.
[88] C. Humpel,et al. Nerve growth factor and glial cell line-derived neurotrophic factor restore the cholinergic neuronal phenotype in organotypic brain slices of the basal nucleus of Meynert , 2001, Neuroscience.
[89] E. Arenas,et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene , 1996, Nature.
[90] D. Russell,et al. Potent inhibitory effects of glial derived neurotrophic factor against kainic acid mediated seizures in the rat , 1995, Brain Research.
[91] H. Shibasaki,et al. Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system , 2000, Neuroscience.
[92] J. Engele,et al. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia [published erratum appears in J Neurosci 1992 Mar;12(3):685] , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[93] A. Buj-Bello,et al. Characterization of a multicomponent receptor for GDNF , 1996, Nature.
[94] C. Altar,et al. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[95] J. Langston,et al. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection , 1993, Neuroscience.
[96] I. Fariñas,et al. GFRα1 Is an Essential Receptor Component for GDNF in the Developing Nervous System and Kidney , 1998, Neuron.
[97] R. Oppenheim,et al. The neurotrophic theory and naturally occurring motoneuron death , 1989, Trends in Neurosciences.
[98] Mart Saarma,et al. Defects in enteric innervation and kidney development in mice lacking GDNF , 1996, Nature.
[99] J. Kordower. In vivo gene delivery of glial cell line–derived neurotrophic factor for Parkinson's disease , 2003, Annals of neurology.
[100] D. Russell,et al. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. , 1996, European journal of pharmacology.
[101] D J Brooks,et al. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET , 1995, Neuroreport.
[102] R. Weissleder,et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. , 1995, The American journal of pathology.
[103] Charles Eigenbrot,et al. X-ray structure of glial cell-derived neurotrophic factor at 1.9 Å resolution and implications for receptor binding , 1997, Nature Structural Biology.
[104] N. Belluardo,et al. Complementary and Overlapping Expression of Glial Cell Line-Derived Neurotrophic Factor (GDNF), c-ret Proto-Oncogene, and GDNF Receptor-α Indicates Multiple Mechanisms of Trophic Actions in the Adult Rat CNS , 1997, The Journal of Neuroscience.
[105] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[106] P. J. Condon,et al. Embryonic Precursor Cells That Express Trk Receptors: Induction of Different Cell Fates by NGF, BDNF, NT-3, and CNTF , 1997, Experimental Neurology.
[107] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[108] R. Vandlen,et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.
[109] M. Takahashi,et al. The GDNF/RET signaling pathway and human diseases. , 2001, Cytokine & growth factor reviews.
[110] C. Sortwell,et al. Therapeutic Potential of Nerve Growth Factors in Parkinson’s Disease , 1999, Drugs & aging.
[111] R. Oppenheim,et al. Glial Cell Line-Derived Neurotrophic Factor and Developing Mammalian Motoneurons: Regulation of Programmed Cell Death Among Motoneuron Subtypes , 2000, The Journal of Neuroscience.
[112] L. Olson,et al. Characterization of a fibrin glue-GDNF slow-release preparation. , 1998, Cell transplantation.
[113] H. Bujard,et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[114] J. Lavail,et al. Endocytosis of Activated TrkA: Evidence that Nerve Growth Factor Induces Formation of Signaling Endosomes , 1996, The Journal of Neuroscience.
[115] R. Grondin,et al. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease , 1998, Journal of Neurology.
[116] M. Saarma,et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. , 2000, Science.
[117] J. Ridet,et al. Gene transfer techniques for the delivery of GDNF in Parkinson's disease. , 2000, Novartis Foundation symposium.
[118] T. Deacon,et al. Neural transplantation studies reveal the brain's capacity for continuous reconstruction , 1997, Trends in Neurosciences.
[119] H. Mizukami,et al. Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis , 2002, The Journal of Neuroscience.
[120] I. Strömberg,et al. Implantation of Bioactive Growth Factor-Secreting Rods Enhances Fetal Dopaminergic Graft Survival, Outgrowth Density, and Functional Recovery in a Rat Model of Parkinson's Disease , 2000, Experimental Neurology.
[121] M. Tuszynski,et al. Growth-factor gene therapy for neurodegenerative disorders , 2002, The Lancet Neurology.
[122] B. Hoffer,et al. Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.
[123] M. Mattson. Neuroprotective Strategies Based on Targeting of Postreceptor Signaling Events , 1998 .
[124] T. Itakura,et al. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor. , 2000, Journal of neurosurgery.
[125] Glial cell line-derived neurotrophic factor promotes the survival and morphologic differentiation of Purkinje cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[126] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[127] D. Hilt,et al. Glial cell line–derived neurotrophic factor–levodopa interactions and reduction of side effects in parkinsonian monkeys , 1997, Annals of neurology.
[128] S. McMahon,et al. A Distinct Subgroup of Small DRG Cells Express GDNF Receptor Components and GDNF Is Protective for These Neurons after Nerve Injury , 1998, The Journal of Neuroscience.
[129] G. Gerhardt,et al. Glial Cell Line-Derived Neurotrophic Factor Increases Stimulus-Evoked Dopamine Release and Motor Speed in Aged Rhesus Monkeys , 2003, The Journal of Neuroscience.
[130] G. Gerhardt,et al. Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates. , 1998, Advances in pharmacology.
[131] D. Morens,et al. Epidemiologic observations on Parkinson's disease , 1996, Neurology.
[132] K. Jellinger,et al. Recent developments in the pathology of Parkinson's disease. , 2002, Journal of neural transmission. Supplementum.
[133] D. Holtzman,et al. Nerve growth factor and the neurotrophic factor hypothesis , 1996, Brain and Development.
[134] Jonas Frisén,et al. Renal agenesis and the absence of enteric neurons in mice lacking GDNF , 1996, Nature.
[135] Y. Smith,et al. Anatomy of the dopamine system in the basal ganglia , 2000, Trends in Neurosciences.
[136] M. Beal,et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[137] J. Milbrandt,et al. Functional Mapping of Receptor Specificity Domains of Glial Cell Line-derived Neurotrophic Factor (GDNF) Family Ligands and Production of GFRα1 RET-specific Agonists* , 2000, The Journal of Biological Chemistry.
[138] D. F. Howard,et al. Gene Therapeutic Strategies for Neuroprotection: Implications for Parkinson's Disease , 1997, Experimental Neurology.
[139] M. Ulfendahl,et al. Adenoviral and adeno-associated viral vector mediated gene transfer in the guinea pig cochlea , 2002, Neuroreport.
[140] J. Kordower,et al. Cellular Delivery of Trophic Factors for the Treatment of Huntington's Disease: Is Neuroprotection Possible? , 1999, Experimental Neurology.
[141] L. Olson,et al. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system , 1996, Cell and Tissue Research.
[142] E. Hirsch,et al. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP‐treated monkeys, and in Parkinson's disease patients , 2000, The Journal of comparative neurology.
[143] H. Phillips,et al. Neurotrophic‐4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures , 1994 .
[144] M. Pelleymounter,et al. Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. , 1996, The Journal of pharmacology and experimental therapeutics.
[145] J. Langston,et al. GDNF Induces a Dystonia-like State in Neonatal Rats and Stimulates Dopamine and Serotonin Synthesis , 1996, Neuron.
[146] G. Yancopoulos,et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.
[147] G. Siegel,et al. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain , 2001, Journal of Chemical Neuroanatomy.
[148] I. Fariñas,et al. Renal and neuronal abnormalities in mice lacking GDNF , 1996, Nature.
[149] J. Milbrandt,et al. GFRα-Mediated Localization of RET to Lipid Rafts Is Required for Effective Downstream Signaling, Differentiation, and Neuronal Survival , 2000, Neuron.
[150] Yi Ai,et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects , 2003, The Journal of comparative neurology.
[151] S. Korsching,et al. The neurotrophic factor concept: a reexamination , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[152] P F Morrison,et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.
[153] D. Brooks,et al. Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain , 2005, Nature Medicine.
[154] X. Breakefield,et al. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease , 1995, Brain Research.
[155] F. Hefti. Is Alzheimer disease caused by lack of nerve growth factor? , 1983, Annals of neurology.
[156] P. Lapchak. Therapeutic Potentials for Glial Cell Line-Derived Neurotrophic Factor (GDNF) Based upon Pharmacological Activities in the CNS , 1996, Reviews in the neurosciences.